IR Notice
Dear Shareholders,
Plant 4 Virtual Showroom Opening
In August, we announced ver exciting news regarding our Plant 4 expansion plan. Due to the onging COVID-19 pandemic, we are not able to invite everyone in person to share our excitement for this new journey we are about to emkark on. And so in light of these challenges, we have created a virtual showroom to introduce key features and many advantages Plant 4 will bring to our clients and to the healthcare industry. Our new Plant 4 is designed as a "Super Plant," showcasing cutting-edge technologies. Plant 4 will serve our customers form every stage, including cell line and process development, to clinical and commercial manufacturing, offering fully integrated, one-stop services. for additional information regarding Plant 4, please visit our newly opened "Plant 4 Virtual Showroom", where you can also track its ongoing construction progress.
Bio CMO/CDO/CRO Champing 2030As a CDMO service provider, Samsung Biologics attained the largest total capacity within the shortest amount of time while ensuring top-notch quality services. We will continue to strengthen our competitive edge through technological innovation and new business development. We will also strive to ensure maximum client satisfaction, optimize shareholder value, and most importantly advance the industry in improving assessibility to healthcare and quality of life. We ask for your continued encouragement and support in buliding a better future with Samsung Biologics. Thank you, Tae Han Kim President & CEO, Samsung Biologics December 3rd, 2020
Dear Shareholders,
Plant 4 Virtual Showroom Opening
In August, we announced ver exciting news regarding our Plant 4 expansion plan. Due to the onging COVID-19 pandemic, we are not able to invite everyone in person to share our excitement for this new journey we are about to emkark on. And so in light of these challenges, we have created a virtual showroom to introduce key features and many advantages Plant 4 will bring to our clients and to the healthcare industry. Our new Plant 4 is designed as a "Super Plant," showcasing cutting-edge technologies. Plant 4 will serve our customers form every stage, including cell line and process development, to clinical and commercial manufacturing, offering fully integrated, one-stop services. for additional information regarding Plant 4, please visit our newly opened "Plant 4 Virtual Showroom", where you can also track its ongoing construction progress.
Bio CMO/CDO/CRO Champing 2030As a CDMO service provider, Samsung Biologics attained the largest total capacity within the shortest amount of time while ensuring top-notch quality services. We will continue to strengthen our competitive edge through technological innovation and new business development. We will also strive to ensure maximum client satisfaction, optimize shareholder value, and most importantly advance the industry in improving assessibility to healthcare and quality of life. We ask for your continued encouragement and support in buliding a better future with Samsung Biologics. Thank you, Tae Han Kim President & CEO, Samsung Biologics December 3rd, 2020